Aim Immunotech (AIM) Stock News

AIM ImmunoTech has received a warning notification from NYSE American due to noncompliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has experienced losses in the past five fiscal years. NYSE American requires stockholders' equity of $4.0 million for companies with losses in three of four recent fiscal years, and $6.0 million for those with losses in five recent fiscal years. This follows a previous warning issued in December 2024. AIM has submitted a compliance plan that was accepted by NYSE American, giving the company until June 11, 2026, to meet requirements. The company's stock continues trading under symbol AIM, and the notice does not affect its business operations or SEC reporting requirements.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the resumption of trading of its common stock on the NYSE American exchange effective June 17, 2025. The company's shares are trading under the ticker symbol 'AIM' with CUSIP number 00901B303. The resumption of trading on NYSE American, one of the major U.S. stock exchanges, marks an important milestone for the company's market presence.

AIM ImmunoTech has secured a significant U.S. patent (No. 12312376) for manufacturing therapeutic double-stranded RNA (dsRNA) products, including Ampligen, extending protection until 2041. This patent complements AIM's existing portfolio covering Ampligen's manufacture, composition, and therapeutic applications. The company's IP portfolio includes patents for treating cancer (expires 2039), Post-COVID fatigue (expires 2042), and endometriosis (expires 2040). Additionally, AIM holds multiple Orphan Drug Designations from FDA and EMA, providing 7-10 years of market exclusivity post-approval for conditions including Metastatic Melanoma, Renal Cell Carcinoma, Pancreatic Adenocarcinoma, Ebola Virus Disease, Chronic Fatigue Syndrome, and HIV.

AIM ImmunoTech (NYSE American: AIM) announced that NYSE Regulation has withdrawn its delisting determination and will lift the trading suspension of the company's common stock. The decision comes after the company's stock price rose above the minimum threshold required by Section 1003(f)(v) of the NYSE American Company Guide. Trading of AIM's common stock is set to resume on the NYSE American on Tuesday, June 17, 2025, under the symbol 'AIM' with CUSIP 00901B303. This development marks a significant turnaround for the company, ensuring its continued listing on a major exchange.

AIM ImmunoTech (NYSE: AIM) has announced a 1-for-100 reverse stock split effective June 12, 2025. The primary objective is to boost the company's per-share market price to regain compliance with NYSE American's Listing Qualifications. The split was approved by stockholders at a Special Meeting on April 30, 2025. Following the split, the company's OTC Pink ticker will temporarily change to AIMID for 20 trading days. Stockholders will receive cash for any fractional shares post-split. The company's common stock will maintain its $0.001 par value but will be assigned a new CUSIP number: 00901B303.

AIM ImmunoTech (NYSE: AIM) presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists. Dr. Pawel Kalinski's presentation highlighted Ampligen's unique two-level selectivity when combined with PD-1 blockade or chemotherapy. The drug demonstrated the ability to: 1. Selectively induce CTL-attracting chemokines without triggering counterproductive Treg-attracting chemokines 2. Preferentially activate cancer tissues over healthy tissues The research showed that Ampligen's selective impact on tumor microenvironment stems from its ability to avoid helicase-dependent activation of NFkB, differentiating it from poly-I:C and other TLR ligands.

AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.

The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.

AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on cancer, immune disorders, and viral diseases therapeutics, announced receiving a delisting notification from NYSE American on April 4, 2025. The Exchange suspended trading of AIM's common stock due to its low selling price, citing Section 1003(f)(v) of the NYSE American Company Guide.

The company plans to appeal the determination to the Exchange's Listing Qualifications Panel, though success is not guaranteed. Trading of AIM's common stock is expected to transition to the Pink Open Market starting April 7, 2025.

AIM ImmunoTech (NYSE: AIM) has reported its Q4 and full year 2024 financial results, highlighting progress in its Ampligen clinical development programs. The company ended 2024 with $4.0 million in cash and investments, down from $13.1 million in 2023. Financial metrics show reduced expenses, with R&D costs decreasing to $6.2 million from $10.9 million and G&A expenses dropping to $13.7 million from $21.1 million year-over-year.

Key developments include the advancement of the DURIPANC Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, and upcoming milestones in multiple clinical trials through 2026. The company is also pursuing studies in refractory melanoma, triple negative breast cancer, and advanced recurrent ovarian cancer, with several trials being partially funded by collaborators including AstraZeneca and Merck.